Navigation Links
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
Date:5/15/2008

BRIDGEWATER, N.J., May 15 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that findings from the landmark ATHENA study showed Multaq(R) (dronedarone), a potential therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased the risk of cardiovascular hospitalizations or death from any cause by a statistically significant 24% (p=0.00000002), meeting the study primary endpoint. The ATHENA results will be presented at the late breaking clinical trial session of Heart Rhythm 2008, the Heart Rhythm Society's 29th Annual Scientific Sessions in San Francisco, USA.

For the first time in twenty years of clinical drug trials in atrial fibrillation, an investigational medicine, Multaq(R), showed a significant decrease in the risk of cardiovascular death by 30% (p=0.03) on top of standard therapy, including rate control and antithrombotic drugs, in patients with atrial fibrillation or atrial flutter. Multaq(R) also significantly decreased the risk for arrhythmic death by 45% (p=0.01), and there were numerically less deaths (16%) from any cause in the dronedarone group compared to placebo (p=0.17). First cardiovascular hospitalization was reduced by 25% (p=0.000000009) in the dronedarone group.

"The ATHENA results have the potential to change the face of atrial fibrillation management. For atrial fibrillation patients, who together with their physicians struggle on a daily basis to manage the dramatic consequences of this complex disease, Multaq(R) carries hope for patients," said Marc Cluzel, sanofi-aventis Senior Vice President, R&D. "This milestone is indicative of sanofi-aventis' commitment to bringing innovative therapies to market, and of our ongoing commitment to provide patients, physicians and public health stakeholders with breakthrough medicines in those therapeutic areas where there are major healthcare needs and limited solutions."

Atrial fibrillation is a major cause o
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

9

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
2. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
3. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
4. Hospital Launches Landmark Emergency Medicine Project
5. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
6. Viatronix V3D-Colon Utilized in Another Landmark Study
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
11. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2009)...ndia,s Breast Cancer Recurrence Test MammaPrint,I...us Recommendations" issued,on 23 Jun 2009 12:00 G...vised,that the subheadline was missing from the r... Complete, corrected release follows: , ,... Recurrence Test MammaPrint Included in,Internati...
(Date:6/25/2009)...xperts Slated to Attend First National Symposium -...e first national symposium designed to explore the... week in New York City when thirteen top experts g...respective fields. The SUNY Youth Sports Institut...th impacts that the $5 billion-a-year energy drink...
(Date:6/25/2009)...Covering ARIKACE for Once-Daily Treatment of Pseud....J., June 25 Cystic Fibrosis Found...f the Cystic Fibrosis Foundation, has provided a $...ued development of ARIKACE(TM) (liposomal amikacin... Pseudomonas lung infections in cystic fibrosis ...
(Date:6/24/2009)... , - Recruitment o...on-Surgical Treatment of Eye Disease With No Repor...ext Brussels: THR), a biotechnology company,focus...treatments for eye,disease, vascular disease and ...roplasmin, which is in Phase III trials for the tr...
Breaking Medicine Technology:/C O R R E C T I O N -- Agendia B.V./ 2/C O R R E C T I O N -- Agendia B.V./ 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 2SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 4Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 2Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 3Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 4ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 2ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 3Genetic Engineering 26 Biotechnology News reports on advances in miRNA 3639 1Catholic Healthcare West and SEIU Begin Negotiations for 15 000 Hospital Workers 13193 1Catholic Healthcare West and SEIU Begin Negotiations for 15 000 Hospital Workers 13193 2Federal District Court Ruling Holding Illinois Parental Notice of Abortion Act of 1995 Unconstitutional 13191 1What are the Odds 3F Friends Give Birth to Leap Year Babies within Hours of Each Other 13188 1
...8, 2007 /PRNewswire-FirstCall/ --,Viragen, Inc. an...lts from a sponsored in vitro study conducted at U...ron(R) (multi-,subtype, human alpha interferon) su...lones to a far greater degree than,recombinant alp...lication in AntiCancer Research, International Jou...
...SINESS WIRE)--May 8, 2007 - AVANIR,Pharmaceuticals...he,efficacy, safety and improvements in patient-ce...al neuropathic (DPN) pain treated,with the investi...dine) will be presented in two scientific posters ...c Pain, being held in,Berlin, Germany on June 7 to...
Other Medicine Technology:Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 2Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 3Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 4AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 4
(Date:7/4/2009)...ealth and fitness need not suffer, , , ...re cutting back in these tough economic times, try...u cut back when it comes to your health? , As i...t about it. There are ways to save money, they say... fit and receiving needed medical care. , Heal...
(Date:7/3/2009)...-- Bertalan Mesko, medical blogger and health 2.0 ...al professionals focusing on how the virtual world... expensive and patients are also open to use virtu...rs enter a virtual realm and organize medical pres...vides opportunities for case presentations, e-lear...
(Date:7/3/2009)...re/ -- Republicans on the Senate Finance Committee...gislation that would eliminate coverage for aborti...e coverage for abortion services that their privat...uninsured women will still lack a basic health car...ality of life. , , If these senators are allowe...
(Date:7/3/2009)...aunches new content to include information about h...st deal with these health issues. , ...everseAges.com has recently launched a new series ...n health issues such as high blood pressure. High ...and the new content on ReverseAges.com addresses t...
Breaking Medicine News(10 mins):Health News:Living Healthily on Less 2Health News:Living Healthily on Less 3Health News:Living Healthily on Less 4
... have shown that twisting the graft to bypass a bl...last longer. In using a graft to bypass blockages,...milar tubes are also used when patients with renal...d a shunt. The problem with the usage of shunt hav...
...sted on humans as the first trials begin this mont...eam from the Department of Biochemistry and Molecu... (NARI) at the University of Melbourne, and Bio21 ...ntial to treat a range of painful conditions. The...
...undertaken by theresearchers at Massachusetts Gene...h, has shown that higher intake of low-fat dairy m...type 2 diabetes, either the body does not producee...gnore the insulin.Insulin is necessary for the bod...
...n developed as a tool to diagnose cancer by scient...archers have also been able to develop a technolog...hrough an easy and not expensive diagnostic test. ...les that control the level of proteins made from t...
Other Medicine News:
Used for internal biliary drainage. Supplied sterile in peel-open packages. Intended for one-time use.
...irectly to the biopsy site helps to identify where...reg; II Tissue Marker is the only marker specifica... Biopsy System. It accurately, permanently, and ra...e MAMMOTOME System. The MICROMARK II Tissue Marker...
...YL knitted mesh. Especially suitable for injuries ...ble absorption. Polyglactin 910 has been found to ... (polyglactin 910) woven mesh is prepared from a s...tide, derived respectively from glycolic and lacti...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: